ICCC Q3 2024 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+11.4% YoY

Gross Profit

$2M26.3% margin

Operating Income

-$574,894-9.6% margin

Net Income

-$701,690-11.7% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+9.8%

Cash Flow

Operating Cash Flow

-$639,331

Free Cash Flow

-$727,743

Stock-Based Comp.

$77,557

Balance Sheet

Total Assets

$44M

Total Liabilities

$18M

Stockholders' Equity

$26M

Cash & Equivalents

$4M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$5M	+11.4%
Gross Profit	$2M	$1M	+25.0%
Operating Income	-$574,894	-$1M	+51.4%
Net Income	-$701,690	-$940,000	+25.4%

Geographic Segments

UNITED STATES

$5M100%